- Home
- NEWT vs TNGX Comparison
NEWT vs TNGX Comparison
Compare NEWT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- TNGX
- Stock Information
- Founded
- NEWT 1998
- TNGX 2014
- Country
- NEWT United States
- TNGX United States
- Employees
- NEWT N/A
- TNGX N/A
- Industry
- NEWT Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- TNGX Health Care
- Exchange
- NEWT Nasdaq
- TNGX Nasdaq
- Market Cap
- NEWT 312.9M
- TNGX 351.2M
- IPO Year
- NEWT N/A
- TNGX N/A
- Fundamental
- Price
- NEWT $11.16
- TNGX $5.88
- Analyst Decision
- NEWT Hold
- TNGX Strong Buy
- Analyst Count
- NEWT 4
- TNGX 6
- Target Price
- NEWT $13.75
- TNGX $12.20
- AVG Volume (30 Days)
- NEWT 191.1K
- TNGX 2.6M
- Earning Date
- NEWT 07-28-2025
- TNGX 08-06-2025
- Dividend Yield
- NEWT 6.81%
- TNGX N/A
- EPS Growth
- NEWT 27.62
- TNGX N/A
- EPS
- NEWT 1.92
- TNGX N/A
- Revenue
- NEWT $352,584,000.00
- TNGX $40,990,000.00
- Revenue This Year
- NEWT N/A
- TNGX N/A
- Revenue Next Year
- NEWT $13.51
- TNGX N/A
- P/E Ratio
- NEWT $5.80
- TNGX N/A
- Revenue Growth
- NEWT 23.06
- TNGX 10.09
- 52 Week Low
- NEWT $9.12
- TNGX $1.03
- 52 Week High
- NEWT $15.49
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- NEWT 47.15
- TNGX 73.28
- Support Level
- NEWT $11.60
- TNGX $5.75
- Resistance Level
- NEWT $12.06
- TNGX $6.40
- Average True Range (ATR)
- NEWT 0.31
- TNGX 0.50
- MACD
- NEWT -0.02
- TNGX -0.03
- Stochastic Oscillator
- NEWT 27.97
- TNGX 83.80
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.